Insider filing
Traded Sep 2 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 4, 2026 · Filed Aug 5, 2026
A Boston Scientific director paid $6.8K out of pocket for Boston Scientific shares. 3 other people at Boston Scientific bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$6,802
Shares × reported transaction price
<$25K
+0.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 3 earlier confirmed purchases
4 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
6 days after results of Jul 29, 2026, 85 days before results of Oct 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $49.09 on Aug 4, 2026, 15% above its 52-week low and 55% below its high, after an 11% rise over the previous 30 trading days
52-week range $42.63 (Jul 14, 2026) to $108.14 (Sep 8, 2025), 10% of the way up, from 251 adjusted closes. 30 trading days earlier: $44.33 on Jun 22, 2026. Describes the past only, not a forecast
RSI 68, 32% under its 200-day average, 6% above its 50-day average, 55% below the 52-week high, 20-day volatility 30% a year, against the S&P 500: +7 points over 1 month, −21 points over 3 months, −57 points over 6 months
From the adjusted closes up to Aug 4, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
3 BSX insiders bought within the same week. That happened 6 times before in filings since 2006, most recently May 2026
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
A securities lawsuit naming the company as a defendant was filed on Mar 5, 2026 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.
2 such cases were open. In re: Boston Scientific Corporation Securities Litigation, docket 1:26-cv-40075, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +4.8% | +1.2% | +3.6% |
| 30 days | −8.8% | −0.3% | −8.4% |
| 90 days | −7.1% | −0.2% | −6.8% |
Past results only. Not a forecast.
Insider filing
Traded Sep 2 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Sep 2 · filed 1 day later
Routine share withholding; mechanical by default.
Insider filing
Traded Sep 2 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
David C Habiger, Director's past purchases, 90 days after disclosure: 5 buys, median −6.8 pts vs S&P 500, beat it 1 of 5 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.